Abstract:Upon recognition of microbial DNA or self-DNA, the cyclic-GMP-AMP synthase (cGAS) of the host catalyzes the production of the cyclic dinucleotide cGAMP. cGAMP is the main activator of STING, stimulator of interferon genes, leading to interferon synthesis through the STING-TBK1-IRF3 pathway. STING is also a hub for activation of NF-κB and autophagy. The present review details the striking similarities between T and B cell responses in severe coronavirus disease 2019 (COVID-19) and both animal or human models of STING gain of function (SAVI syndromes: STING-associated vasculopathy with onset in infancy). Those similarities may be further clues for a delayed activation of STING in severe COVID-19 patients, due to DNA damages following severe acute respiratory syndrome coronaviruses (SARS-CoV-2) infection and unusual role of STING in SARS-CoV-2 control. In early stages, Th2 differentiation are noticed in both severe COVID-19 and SAVI syndromes; then, CD4+ and CD8+ T cells functional exhaustion/senescent patterns due to TCR hyper-responsiveness are observed. T cell delayed over-responses can contribute to pneumonitis and delayed cytokine secretion with over-production of IL-6. Last, STING over-activation induces progressive CD4+ and CD8+ T lymphopenia in SAVI syndromes, which parallels what is observed in severe COVID-19. ACE2, the main receptor of SARS-CoV-2, is rarely expressed in immune cells, and it has not been yet proven that some human lymphocytes could be infected by SARS-CoV-2 through CD147 or CD26. However, STING, expressed in humans T cells, might be triggered following excessive transfer of cGAMP from infected antigen presenting cells into activated CD4+ and CD8+ T cells lymphocytes. Indeed, those lymphocytes highly express the cGAMP importer SLC19A1. Whereas STING is not expressed in human B cells, B cells counts are much less affected, either in COVID-19 or SAVI syndromes. The recognition of delayed STING over-activation in severe COVID-19 patients could prompt to target STING with specific small molecules inhibitors already designed and/or aspirin, which inhibits cGAS.

Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING?

The cGAS–STING pathway drives type I IFN immunopathology in COVID-19

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Involvement of the STING Signaling in COVID-19

SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB

Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection

Targeting the cGAS-STING pathway as an inflammatory crossroad in coronavirus disease 2019 (COVID-19)

A basally active cGAS-STING pathway limits SARS-CoV-2 replication in a subset of ACE2 positive airway cell models

SARS-CoV-2 spike protein–induced cell fusion activates the cGAS-STING pathway and the interferon response

Aggravating mechanisms from COVID-19

SARS‐CoV‐2 ORF10 antagonizes STING‐dependent interferon activation and autophagy

Suppression of systemic autoimmunity by the innate immune adaptor STING

Lymphopenia drives T cell exhaustion in immunodeficient STING gain-of-function mice

Activation of autoreactive lymphocytes in the lung by radioresistant cells expressing a STING gain-of-function mutation

Interruption of Post-Golgi STING Trafficking Activates Tonic Interferon Signaling

Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins

Severe COVID-19 and long COVID are associated with high expression of STING, cGAS and IFN-α

Degree of STING activation is associated with disease outcomes

SARS-CoV-2, HIV, and HPV: Convergent Evolution of Selective Regulation of Cgas-Sting Signaling.

Advances in the Prerequisite and Consequence of STING Downstream Signalosomes

Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response